Breast Cancer

Reports from Boston University advance knowledge in breast cancer

Published in Women's Health Weekly, July 3rd, 2008

"CDKNIC ( also known as p57(KIP2)) is a cyclin-dependent kinase inhibitor previously implicated in several types of human cancer. Its family members ( CDKNIA/ p21(CIPI) and B/ p27(KIPI)) have been implicated in breast cancer, but information about CDKNIC's role is limited," scientists in the United States report.

"We hypothesized that decreased CDKNIC may be involved in human breast carcinogenesis in vivo. We determined rates of allele imbalance or loss of heterozygosity ( AI/LOH) in CDKNIC, using an intronic polymorphism, and in the surrounding II p15.5 region in 82 breast cancers. We examined the CDKNIC mRNA level in 10 cancers using quantitative real-time PCR (...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2008-07-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry